ZBH

Business Context and Reporting Period

Company: Zimmer Biomet Holdings, Inc. (ZBH)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Year ended December 31, 2024
Business Overview: A global medical technology leader designing, manufacturing, and marketing orthopedic reconstructive products, sports medicine, biologics, extremities, trauma, craniomaxillofacial, and thoracic products, alongside digital and robotic technologies. The company operates through three segments: Americas, EMEA, and Asia Pacific.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 3.8% year-over-year, driven by market growth, new product introductions, and positive price realization. This growth was partially offset by a 1.0% negative impact from foreign currency exchange rates and operational disruptions from a new ERP implementation in the U.S. and Canada.
• Profitability Decline: Net earnings decreased 11.7% to $903.8 million. The decline was primarily driven by a higher effective tax rate (12.7% vs. 4.0% in 2023) due to the absence of favorable tax settlements seen in the prior year, higher restructuring charges ($219.0 million in 2024 vs. $151.9 million in 2023), and increased intangible asset amortization.
• Segment Performance:
  • Americas: Sales up 3.7%; Operating profit up 3.6%.
  • EMEA: Sales up 6.2%; Operating profit up 8.8%.
  • Asia Pacific: Sales up 1.3%; Operating profit up 5.9%.
• Product Mix: S.E.T. (Sports Medicine, Extremities, Trauma) sales grew 6.5%, while Knees grew 4.4% and Hips grew 1.6%.

Guidance, Outlook, and Risks

2025 Outlook:

• Revenue: Expected year-over-year growth of 1.0% to 3.5%, driven by market growth and new products. Foreign currency is expected to negatively impact sales by 1.5% to 2.0%.
• Operating Profit: Expected to increase due to higher sales, fixed cost leverage, and restructuring savings, partially offset by higher amortization, interest expense, and a higher effective tax rate.

Material Risks and Contingencies:

• ERP Implementation: Transition to a new ERP system in July 2024 caused operational challenges, order fulfillment delays, and increased costs, though shipping levels normalized by year-end.
• Acquisition of Paragon 28: In January 2025, the company agreed to acquire Paragon 28, Inc. for approximately $1.2 billion, expected to close in H1 2025. Financing includes new debt issuances in February 2025.
• Legal Proceedings: Significant product liability litigation remains regarding the Durom Cup, M/L Taper hip stems, and Biomet metal-on-metal hip implants. Accrued litigation liabilities were $156.4 million as of December 31, 2024.
• Tax Disputes: The IRS has proposed adjustments for tax years 2013–2019, including a potential $312 million tax expense for 2016–2019 related to the taxation of foreign earnings. The company intends to vigorously contest these.
• Regulatory Environment: Ongoing compliance with EU Medical Device Regulation (EU MDR) and FDA requirements remains a key operational focus and cost driver.

Investor Verification Checklist

• ERP Impact Resolution: Verify that the operational disruptions from the ERP implementation have fully stabilized and that customer trust has been regained.
• Paragon 28 Integration: Monitor the closing timeline and integration progress of the Paragon 28 acquisition, including the realization of anticipated synergies.
• Tax Liability Exposure: Track the status of IRS audits for tax years 2013–2019 and the potential impact of the proposed $312 million adjustment on future cash flows.
• Restructuring Execution: Confirm the realization of the projected $175–$200 million in annual pre-tax operating expense savings from the 2023 Restructuring Plan.
• Product Liability Reserves: Review updates on the Durom Cup and metal-on-metal hip implant litigation to ensure accrued reserves remain adequate.